View Clinical Trial (Medical Research Study)

Generalized Anxiety and Seroquel - NCT01066143-02478(Clinical Trial 494282)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Belmont
State:  
MA
Zip Code: 02478
Conditions: Generalized Anxiety Disorder - Seroquel XR
Purpose: The 12 week clinical trial of Seroquel in Generalized Anxiety Disorder (GAD) patients will be combined with fMRI experiments.
Study summary: Subjects will be recruited from clinic patients and known research subjects at McLean Hospital, as well as by advertisements in the media, flyers, and word of mouth. An initial telephone interview will be conducted to determine if potential subjects meet the basic study requirements. Subjects will be also screened for drug use. If no obvious health problems are present, subjects will be scheduled for an evaluation. Upon arrival at the research unit, each subject will first complete a standardized interview schedule designed to obtain personal and background data such as age, marital status, socio-economic status, education, employment, etc. The Research Assistant will give subjects both verbal and written descriptions of the study procedures. After briefing subjects on the reasons for the research, subjects will be given the opportunity to ask questions. When they are ready, subjects will be asked to sign the written informed consent form approved by the Mclean Institutional Review Board (IRB). Functional magnetic resonance imaging scans to examine brain functioning will be obtained from GAD patients (N=30) at baseline and after 12 weeks. Seroquel XR tablets will be flexibly dosed and begun at a target dose of 50 mg on day 1, 100 mg on day 2, 150 mg on day 3 and 200 mg on day 4 with a maximal daily dose of 400 mg on subsequent days.
Criteria: Inclusion Criteria: - Provision of written informed consent - Fluency in English - A diagnosis of GAD - No pregnancy - Right-handedness - Psychotropic medication-free at the start of the study Exclusion Criteria: - Pregnancy or lactation - Any current DSM-IV-TR Axis I disorder - Any mental retardation or cognitive impairment that precludes informed consent - Known intolerance or lack of response to quetiapine fumarate - Substance or alcohol dependence at enrollment - Participation in another drug trial within 4 weeks prior enrollment - History of allergic reaction or hypersensitivity to Seroquel or Seroquel XR - History of prior Seroquel or other antipsychotic agents use - Contraindications to magnetic resonance imaging - Treatment with an effective medication for GAD
Study is available at: McLean Hospital
Belmont, MA 02478
United States

Primary Contact:
Evelyne Tschibelu, BS
Email: etschibelu@mclean.harvard.edu
Phone: 617-855-3370

Secondary Contact:
Evelyne Tschibelu, BS
Email: etschibelu@mclean.harvard.edu
Phone: 617-855-3370
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 23, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.